Robert Wasserman

Stock Analyst at Benchmark

(1.68)
# 1437
Out of 5,240 analysts
115
Total ratings
53.73%
Success rate
14.14%
Average return
23 Stocks
Name Action Price Target Current % Upside Ratings Updated
Ligand Pharmaceutica...
Reiterates: Buy
135 135
108.66 24.24% 10 Dec 23, 2024
BioLife Solns
Reiterates: Buy
30 30
26.19 14.55% 6 Dec 19, 2024
Anebulo Pharmaceutic...
Reiterates: Speculative Buy
8 8
1.6 400% 6 Nov 19, 2024
OmniAb
Reiterates: Buy
8 8
3.19 150.78% 7 Nov 14, 2024
Nephros
Reiterates: Speculative Buy
5 5
1.5 233.33% 3 Nov 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
8 12
9.37 28.07% 17 Nov 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 5 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 7 Nov 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
140 140
138.55 1.05% 9 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Speculative Buy
5 3
0.45 566.67% 5 Aug 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
95 95
74.74 27.11% 5 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
60 60
53.76 11.61% 7 Aug 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 3 Aug 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Speculative Buy
12 12
2.64 354.55% 6 Jul 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
45 45
37.01 21.59% 6 May 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Speculative Buy
4
3.27 22.32% 1 Mar 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Speculative Buy
4
0.81 393.83% 1 Mar 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Speculative Buy
7
n/a n/a 1 May 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Speculative Buy
75
1.89 3868.25% 2 Apr 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 3 Oct 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Speculative Buy
7
n/a n/a 3 Aug 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
580
557.25 4.08% 1 Jul 16, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
1386
n/a n/a 1 Aug 28, 2018